All News

Naloxone is available, but is it actually being used?

Pharmacists are now recognized as providers nearly everywhere-now that they have the status, what does it mean?

What do you do about the customer who is never satisfied?

Is Trump focusing on the wrong thing?

The length of an initial opioid prescription influences the risks of long-term use.

How pharmacists can help fight the battle.

The New Drug Review for April

Cardiac Matters-What you need to know about anakinra

How Trinity Health and Pacira are minimizing opioid use.

The citizens petition process is being used to delay approval of generic drugs.

How physicians made millions and fed the opioid epidemic.

New legislation could be a model for other states.

23andMe recently gained FDA approval, but will it actually help keep people healthier?

The chain has said it remains committed to buying Rite Aid stores.

A reporter earned the biggest journalism prize covering the opioid crisis.

Supervalu’s diabetes campaign offers risk assessments, screening, and food education.

New class of glucose-lowering agents lowers hospitalization and death rates even in Type 2 patients without heart disease.

Trump and Gottlieb are both taking steps to end the opioid epidemic. But is it enough?

Small Doses is news for pharmacists in a way that works for you.

What the new company will mean for specialty pharmacy.

Why a drug that costs $65,000 a year is making patient groups happy.

Nearly 600,000 inhalers are being recalled.

Two previous reports of device failures lead EpiPen maker to expand recall to the United States.

What we know-and what we don't-about antibiotics in America.

Even medical marijuana has health-care costs and outcomes.

How a program hopes to cut errors in half.

Ontario joins Nova Scotia in making medication dispensing error reporting mandatory, but no states have enacted similar laws.